Clinical Breast Cancer · 2019 · 35 citations · 15 references
MedicineOncologyPharmacologyBreast OncologyClinical PharmacologyMolecular OncologyBreast Cancer PharmacotherapyCancer ImmunotherapyHer2-positive Breast CancerImmunotherapy For Breast CancerMetastatic Breast CancerTyrosine Kinase InhibitorsHer2 InhibitorsHer2 Receptor SignalingHer2-positive Breast Cancer ImmunotherapyHer2-positive Breast Cancer TherapyHormone Receptor-positive Breast Cancer TherapyHuman Epidermal Growth Factor Receptor 2-Targeted TherapyMetastatic Her2-positive Breast Cancer
15
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. Eisenhauer, P. Therasse, Jan Bogaerts et al. · European Journal of Cancer · 2008 · 29.5K citations
Antonio C. Wolff, M. Elizabeth Hammond, David G. Hicks et al. · Journal of Clinical Oncology · 2013 · 4.1K citations · Full text
Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
Sunil Verma, David Miles, Luca Gianni et al. · New England Journal of Medicine · 2012 · 3.8K citations · Full text
Medicine, Oncology, Pharmacology +14
Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer
Sandra M. Swain, José Baselga, Sung‐Bae Kim et al. · New England Journal of Medicine · 2015 · 2.1K citations · Full text
Medicine, Oncology, Pharmacotherapy +17